|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.
|
21716162 |
2011 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.
|
21716162 |
2011 |
|
gliosarcoma
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
|
9766669 |
1998 |
|
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population.
|
28513222 |
2017 |
|
Hypertensive disease
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Overall, nifedipine and verapamil blunts CSA hypertension but variably affected concomitantly enhanced EDHF-dependent renal vasodilations and alterations in CYP2C/CYP4A signaling.
|
28899749 |
2017 |
|
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
Studies with rat genetic models of hypertension pointed to roles for the CYP2C and CYP4A arachidonic acid epoxygenases and ω-hydroxylases in tubular transport, hemodynamics, and blood pressure control.
|
25986599 |
2015 |
|
Hypertensive disease
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Associations between genetically controlled alterations in blood pressure and the activity and/or transcriptional regulation of the kidney Cyp2c AA epoxygenases and Cyp4a omega-hydroxylases revealed a role for these enzymes in the pathophysiology of hypertension, a leading cause of cardiovascular, cerebral, and renal morbidity and mortality.
|
17597703 |
2007 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.
|
28954402 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
Biomarker
|
disease |
BEFREE |
These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid.
|
29023376 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
Biomarker
|
disease |
BEFREE |
CYP2C enzymes are responsible for the oxidative metabolism of a diverse number of drugs for the treatment of type 2 diabetes mellitus, a severe metabolic disorder with high prevalence.
|
21939641 |
2011 |
|
Epilepsy
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We aimed to evaluate the association of non-response to antiepileptic pharmacotherapy with the frequency of variant alleles in the drug transporter genes ABCB1 and ABCC2 or in the CYP2C locus in young patients with epilepsy and an independent cohort of adults with drug-refractory epilepsy.
|
19415824 |
2009 |
|
Epilepsy
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
|
9333104 |
1997 |
|
Epilepsy
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
|
8874828 |
1996 |
|
Metabolic Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Furthermore, ATR induced CYP-related enzymes metabolism disorders by activating the nuclear xenobiotic receptors response (NXRs including AHR, CAR, and PXR) and increased expression of several CYP isoforms (including CYP1B1 and CYP2C18) and thereby producing mitochondrial dysfunction.
|
29865786 |
2018 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
This study investigated the prognostic value of CYP2C subfamily gene expression levels with HCC prognosis.
|
29479826 |
2018 |
|
Retinal Diseases
|
0.020 |
PosttranslationalModification
|
group |
BEFREE |
Soluble epoxide hydrolase inhibition, which blocks breakdown and inactivation of CYP2C ω-3 LCPUFA-derived active metabolites, increased oxygen-induced retinopathy and CNV in vivo.
|
27417579 |
2016 |
|
Retinal Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
We found that CYP2C (localized in wild-type monocytes/macrophages) is upregulated in oxygen-induced retinopathy, whereas sEH is suppressed, resulting in an increased retinal epoxide:diol ratio.
|
24458713 |
2014 |
|
Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
CYP2C enzymes are responsible for the oxidative metabolism of a diverse number of drugs for the treatment of type 2 diabetes mellitus, a severe metabolic disorder with high prevalence.
|
21939641 |
2011 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The first group contained 11 CYPs, including the CYP2C and CYP4F families, that showed decreased expression in parallel with progression of HCV-infected liver to HCC with less differentiation.
|
16077914 |
2005 |
|
Sudden infant death syndrome
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The amount of RNA encoding CYP2C9 (4.4x control), 2C8 (2.5x) and 2C18 (2.3x) was markedly higher in SIDS than in age-matched children and would suggest a transcriptional activation of CYP2C gene expression.
|
9864383 |
1999 |
|
Sudden infant death syndrome
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The precocious expression of CYP2C in SIDS could result in a higher production of epoxyeicosatrienoic acids in the neonate, believed to act as relaxant of pulmonary smooth muscles.
|
8687505 |
1996 |
|
Cholestasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The constitutive androstane receptor (CAR)/pregnane X receptor (PXR)-CYP2B/CYP2C axis is activated in DKO livers but not in other cholestasis models.
|
29718219 |
2018 |
|
Ulcerative Colitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study indicated that the presence of UC decreases CYP2C expression levels in the liver, thereby delaying the metabolism of CYP2C substrates, including phenytoin, and increasing blood concentrations of these substrates.
|
29130833 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further multicenter studies and large prospective observational studies are, however, still required to determine the influence of CYP2C*3 on blood levels of PHT and its metabolites, and their association with SJS/TEN.
|
29274302 |
2018 |
|
Schwartz-Jampel Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further multicenter studies and large prospective observational studies are, however, still required to determine the influence of CYP2C*3 on blood levels of PHT and its metabolites, and their association with SJS/TEN.
|
29274302 |
2018 |